{"id":406999,"date":"2020-12-31T16:12:33","date_gmt":"2020-12-31T21:12:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=406999"},"modified":"2020-12-31T16:12:33","modified_gmt":"2020-12-31T21:12:33","slug":"repare-therapeutics-insiders-establish-automatic-securities-disposition-plans","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/","title":{"rendered":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside; }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\n\u00a0<b>Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans<\/b><\/p>\n<p>CAMBRIDGE, Mass. &amp; MONTREAL, Quebec&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRepare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business &amp; Corporate Development Kim Seth (collectively, the \u201cExecutives\u201d), as well as certain other insiders of the Company (the \u201cOther Insiders\u201d and collectively with the Executives, the \u201cParticipants\u201d), have established Automatic Securities Disposition Plans (\u201cASDPs\u201d) in accordance with applicable United States and Canadian securities legislation, including the recommended practices set forth in the recently issued Canadian Securities Administrators\u2019 Staff Notice 55-317(\u201cStaff Notice 55-317\u201d) and the Company\u2019s internal policies.\n<\/p>\n<p>\nWhile Repare is listed on the Nasdaq Global Select Market, it is also considered a reporting issuer under the Securities Act (Qu\u00e9bec) and is therefore announcing the establishment of the ASDPs in furtherance of the recently published guidance provided by the Canadian Securities Administrators in Staff Notice 55-317.\n<\/p>\n<p>\nUnder U.S. and Canadian securities laws and the Company\u2019s trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company. The ASDPs address this issue by permitting trades to be made in accordance with pre-arranged instructions given when Participants are not in possession of any material undisclosed information.\n<\/p>\n<p>\nUp to 211,931 common shares of Repare may be sold under the ASDPs implemented by the Executives in the aggregate, and up to 227,341 common shares of Repare may be sold under the ASDPs implemented by the Other Insiders. The ASDPs are designed to allow for an orderly disposition of each of the Participants\u2019 shares in Repare at prevailing market prices over the course of the 12 to 24 months that the ASDPs are expected to be in place. Sales of the common shares under the ASDPs will only commence after the Company has filed its next annual financial statements for the fiscal year ended December 31, 2020, in accordance with the recent recommended practices set forth in Staff Notice 55-317.\n<\/p>\n<p>\nEach Participant has provided for clear trading parameters and other instructions in writing to the independent dealers administering the ASDPs, specifying the number of securities to be sold and setting out minimum trade prices, which in most cases exceed the current trading price of the Company\u2019s common shares, and the dates or frequencies of sales. The ASDPs prohibit the dealer administering the ASDPs from consulting with the Participants regarding any sales under the ASDPs and prohibit the Participants from disclosing to the dealer any information concerning the Company that might influence the execution of the ASDPs.\n<\/p>\n<p>\nThe ASDPs contain meaningful restrictions on the ability of the Participants to amend, suspend or terminate the ASDPs that have the effect of ensuring that the Participants cannot benefit from material non-public information..\n<\/p>\n<p><b>About Repare Therapeutics, Inc.<\/b><\/p>\n<p>\nRepare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx\u00ae platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company\u2019s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol\u03b8 inhibitor programs. For more information, please visit reparerx.com.\n<\/p>\n<p>\nSNIPRx\u00ae is a registered trademark of Repare Therapeutics, Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201231005240\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201231005240\/en\/<\/a><\/span><\/p>\n<p><b>Repare Contact:<br \/>\n<br \/>Steve Forte<br \/>\n<\/b><br \/>Chief Financial Officer<br \/>\n<br \/>Repare Therapeutics, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:info@reparerx.com\">info@reparerx.com<\/a><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Kimberly Minarovich<br \/>\n<br \/>Argot Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:repare@argotpartners.com\">repare@argotpartners.com <\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>David Rosen<br \/>\n<br \/>Argot Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:david.rosen@argotpartners.com\">david.rosen@argotpartners.com<br \/>\n<\/a><br \/>212-600-1902\n<\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans CAMBRIDGE, Mass. &amp; MONTREAL, Quebec&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business &amp; Corporate Development Kim Seth (collectively, the \u201cExecutives\u201d), as well as certain other insiders of the Company (the \u201cOther Insiders\u201d and collectively with the Executives, the \u201cParticipants\u201d), have established Automatic Securities Disposition Plans (\u201cASDPs\u201d) in accordance with applicable United States and Canadian &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-406999","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans CAMBRIDGE, Mass. &amp; MONTREAL, Quebec&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business &amp; Corporate Development Kim Seth (collectively, the \u201cExecutives\u201d), as well as certain other insiders of the Company (the \u201cOther Insiders\u201d and collectively with the Executives, the \u201cParticipants\u201d), have established Automatic Securities Disposition Plans (\u201cASDPs\u201d) in accordance with applicable United States and Canadian &hellip; Continue reading &quot;Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-31T21:12:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans\",\"datePublished\":\"2020-12-31T21:12:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/\"},\"wordCount\":658,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/\",\"name\":\"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-31T21:12:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/","og_locale":"en_US","og_type":"article","og_title":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk","og_description":"\u00a0Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans CAMBRIDGE, Mass. &amp; MONTREAL, Quebec&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business &amp; Corporate Development Kim Seth (collectively, the \u201cExecutives\u201d), as well as certain other insiders of the Company (the \u201cOther Insiders\u201d and collectively with the Executives, the \u201cParticipants\u201d), have established Automatic Securities Disposition Plans (\u201cASDPs\u201d) in accordance with applicable United States and Canadian &hellip; Continue reading \"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-31T21:12:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans","datePublished":"2020-12-31T21:12:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/"},"wordCount":658,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/","name":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-31T21:12:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201231005240r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-insiders-establish-automatic-securities-disposition-plans\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=406999"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=406999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=406999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=406999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}